Xbrane Biopharma AB

XBRANE

SE0007789409

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-09-06 pm EDT			5-day change	1st Jan Change
0.1318 ^SEK	-5.18%		-11.54%	-98.68%

Aug. 28	Transcript : Xbrane Biopharma AB, H1 2024 Earnings Call, Aug 28, 2024
Aug. 28	Xbrane Biopharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Xbrane Biopharma AB

Transcript : Xbrane Biopharma AB, H1 2024 Earnings Call, Aug 28, 2024	Aug. 28
Xbrane Biopharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 28	CI
Xbrane Biopharma to Out-License Two Biosimilar Candidates for Financing Purposes	Aug. 12	MT
Xbrane to Regain Full Rights to Cimzia Biosimilar After Biogen Ends Commercialization Deal	Aug. 01	MT
Xbrane Biopharma and Biogen Inc. to Terminate the Commercialization and License Agreement	Aug. 01	CI
Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®?	May. 22	CI
Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024	May. 16
Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI
Transcript : Xbrane Biopharma AB - Special Call	May. 13
Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	May. 10	MT
Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director	May. 02	CI
Transcript : Xbrane Biopharma AB - Special Call	Apr. 22
Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index	Mar. 17	CI
Transcript : Xbrane Biopharma AB, 2023 Earnings Call, Feb 26, 2024	Feb. 26
Xbrane Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Xbrane Biopharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 26	CI
Xbrane Biopharma AB(OM:XBRANE) added to OMX Nordic Small Cap Index	Jan. 04	CI
Xbrane Biopharma AB Announces Appointment of Nomination Committee	Dec. 20	CI
Transcript : Xbrane Biopharma AB, Nine Months 2023 Earnings Call, Nov 30, 2023	Nov. 30
Xbrane Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 30	CI
Xbrane Biopharma AB Focuses on Development Portfolio and Introduces A Cost-Savings Scheme	Nov. 23	CI
Xbrane Biopharma AB Presents Nomination Committee	23-10-18	CI
Transcript : Xbrane Biopharma AB, H1 2023 Earnings Call, Aug 29, 2023	23-08-29
Xbrane Biopharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Certain Shares of Xbrane Biopharma AB are subject to a Lock-Up Agreement Ending on 21-AUG-2023.	23-08-20	CI

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-10-24 - Q3 2024 Earnings Release

More about the company